scholarly journals Clinical characteristics of argyrophillic grain disease and senile dementia of the neurofibrillary tangle type

2012 ◽  
Vol 49 (3) ◽  
pp. 281-283
Author(s):  
Hiroyuki Shimada
Keyword(s):  
Clinical Characteristics ◽  
Senile Dementia ◽  
Neurofibrillary Tangle ◽  
Senile Dementia Of The

An autopsy case of a centenarian with the pathology of senile dementia of the neurofibrillary tangle type

2016 ◽  
Vol 17 (2) ◽  
pp. 126-129
Author(s):  
Yasushi Iwasaki ◽  
Akira Deguchi ◽  
Keiko Mori ◽  
Masumi Ito ◽  
Maya Mimuro ◽  
...  
Keyword(s):  
Senile Dementia ◽  
Neurofibrillary Tangle ◽  
Autopsy Case ◽  
Senile Dementia Of The

Dementia of the Alzheimer type and related dementias in the aged: DAT subgroups and senile dementia of the neurofibrillary tangle type

1996 ◽  
Vol 16 (2) ◽  
pp. 89-98 ◽  
Author(s):  
Masahito Yamada ◽  
Yoshinori Itoh ◽  
Eiichi Otomo ◽  
Naomi Suematsu ◽  
Masaaki Matsushita
Keyword(s):  
Senile Dementia ◽  
Neurofibrillary Tangle ◽  
Alzheimer Type ◽  
Senile Dementia Of The

Senile Dementia of the Neurofibrillary Tangle Type: A Comparison with Alzheimer’s Disease

2001 ◽  
Vol 12 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Masahito Yamada ◽  
Yoshinori Itoh ◽  
Nobuyuki Sodeyama ◽  
Naomi Suematsu ◽  
Eiichi Otomo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Senile Dementia ◽  
Neurofibrillary Tangle ◽  
Type A ◽  
Senile Dementia Of The

scholarly journals Neurotransmitter and Receptor Deficits in Senile Dementia of the Alzheimer Type

1986 ◽  
Vol 13 (S4) ◽  
pp. 503-510 ◽  
Author(s):  
R. Quirion ◽  
J.C. Martel ◽  
Y. Robitaille ◽  
P. Etienne ◽  
P. Wood ◽  
...  
Keyword(s):  
Neuropeptide Y ◽  
Receptor Binding ◽  
Binding Sites ◽  
Senile Dementia ◽  
Somatostatin Receptor ◽  
Brain Regions ◽  
Nucleus Basalis ◽  
Nicotinic Cholinergic Receptors ◽  
Senile Dementia Of The

Abstract:Multiple neurotransmitter systems are affected in senile dementia of the Alzheimer's type (SDAT). Among them, acetylcholine has been most studied. It is now well accepted that the activity of the enzyme, choline acetyltransferase (ChAT) is much decreased in various brain regions including the frontal and temporal cortices, hippocampus and nucleus basalis of Meynert (nbm) in SDAT. Cortical M2-muscarinic and nicotinic cholinergic receptors are also decreased but only in a certain proportion (30-40%) of SDAT patients. For other systems, it appears that cortical serotonin (5-HT)-type 2 receptor binding sites are decreased in SDAT. This diminution in 5-HT2 receptors correlates well with the decreased levels of somatostatin-like immunoreactive materials found in the cortex of SDAT patients. Cortical somatostatin receptor binding sites are decreased in about one third of SDAT patients. Finally, neuropeptide Y and neuropeptide Y receptor binding sites are distributed in areas enriched in cholinergic cell bodies and nerve fiber terminals and it would be of interest to determine possible involvement of this peptide in SDAT. Thus, it appears that multi-drug clinical trials should be considered for the treatment of SDAT.

Sign in / Sign up

Export Citation Format

Share Document